Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)

  • days left to enroll
  • participants needed
  • sponsor
    Hospices Civils de Lyon
Updated on 6 April 2021


For patients with advanced/metastatic gastric adenocarcinomas in progression after a first line chemotherapy comprising platinum and fluoropyrimidine, the reported second line treatments are : 1) paclitaxel combined with ramucirumab (overall response rate (ORR) = 25%; median progression free survival (PFS) = 2.9 months; median overall survival (OS)= 5.9 months), or paclitaxel alone (ORR = 14%, median PFS = 2.9 months; median OS= 5.9 months); 2) docetaxel (ORR = 7%, median OS = 5.2 months) or 3) irinotecan (ORR = 0%, median OS= 4.0 months).

These numbers demonstrate the poor prognosis of this disease, and the unmet medical need for innovative therapeutic strategies.

Cancer Genome Atlas (TCGA) mapped a genomic landscape of gastric adenocarcinomas, and identified 4 sub-types:

  • Tumor positive for Epstein-Barr virus (EBV) (8%), which display recurrent PIK3CA mutations, extreme DNA hypermethylation, and amplification of JAK2, ErbB2, PD-L1 and PD-L2;
  • Microsatellite instable tumors (MSI-high) (22%), which show elevated mutation rates, including mutations of genes encoding targetable oncogenic signaling proteins (PIK3CA, ErbB2, ErbB3, and EGFR);
  • Genomically stable tumors (20%), which are enriched for the diffuse histological variant and mutations of RHOA or fusions involving RHO-family GTPase-activating proteins;
  • Tumors with chromosomal instability (50%), which show marked aneuploidy and focal amplification of receptor tyrosine kinases and VEGFA.

Most of diffuse-type gastric adenocarcinomas were classified in genomically stable tumors. This subgroup of cancers, accounting for about 20 to 30% of gastric adenocarcinomas, is associated with particularly poor prognosis and resistance to chemotherapy. A proteomic landscape of diffuse-type gastric adenocarcinomas was recently reported.

Pembrolizumab, an anti-PDL1 drug granted with an accelerated approval by FDA in September 2017, exhibited promising activity in gastric adenocarcinoma patients previously treated with 1 or 2 lines of chemotherapy (ORR=11.6%, median PFS = 2.0 months, median OS= 5.6 months), especially in those with PDL1 positive tumors (ORR=22.7%). The tumor response was particularly high in patients with MSI-high tumor (ORR=57.1%). However the preliminary outcomes of the phase III KEYNOTE-061 trial (NCT02370498) recently released in the press suggest that pembrolizumab was not superior to paclitaxel in 592 patients with advanced gastric or gastroesophageal junction adenocarcinoma whose disease progressed after first-line treatment with platinum and fluoropyrimidine doublet therapy (the hazard ratio (HR) for OS was 0.82 (95% confidence interval = 0.66-1.03; one sided P = .042) (

These outcomes suggest that, although being very promising, immunotherapy should be combined to other agents for being fully effective in gastric adenocarcinomas patients.

We propose a strategy based on molecular features to select the drugs that will be associated with atezolizumab, an anti-PDL1 drug, in patients with pre-treated advanced gastric

  • Patients with tumors positive for EBV or microsatellite instable tumors (30%) will be treated with atezolizumab and ipatasertib.
  • Patients with genomically stable tumors (20%) will be treated with atezolizumab combined with bevacizumab.
  • Patients with tumors with chromosomal instability (50%) will be treated with atezolizumab combined with bevacizumab.

Expected outcomes:

IMMUNOGAST trial will provide data about the clinical feasibility of biomolecular characterization of gastric adenocarcinomas for routine treatment adjustment. Moreover it should generate information about the relevance of adjusting combined immunotherapies based on molecular subtypes, in terms of clinical efficacy. Finally, translational research project outcomes should provide important data about relationships between efficacy and tumor immune gene spatial expression, along with tumor and circulating mutational burden. These outcomes may help identify the best candidates for tested combinations in the future.

Condition Gastric Adenocarcinoma, Metastatic Gastric Cancer, Advanced Gastric Carcinoma, Metastatic Adenocarcinoma, metastatic stomach cancer, stomach adenocarcinoma
Treatment Atezolizumab + Ipatasertib, Atezolizumab + Bevacizumab
Clinical Study IdentifierNCT04739202
SponsorHospices Civils de Lyon
Last Modified on6 April 2021


Yes No Not Sure

Inclusion Criteria

Histologically and/or cytologically documented recurrent advanced/metastatic gastric or gastroesophageal junction adenocarcinomas previously treated with a platinum and fluoropyrimidine-based regimen
The gastric or gastroesophageal junction adenocarcinomas that overexpress HER2 should have previously been treated with trastuzumab, except in the case of contraindication
Patients older than 18 years
Patients with Eastern Cooperative Oncology Group (ECOG) performance status 1
Patients must have documented disease progression
Patients who have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Accessible tumor lesion (primitive lesion or metastasis) for trial dedicated tumor biopsy
Left ventricular ejection fraction (LVEF) 50% by echocardiogram (echo) or multigated acquisition (MUGA) scan within 28 days before day 1 of treatment
Child-Pugh class A
Patients must have normal organ and marrow function
Absolute neutrophil count 1,500/L, platelets 100,000/L, hemoglobin 9 g/dL
Total bilirubin 1.5 ULN except subject with documented Gilbert's syndrome, AST(SGOT)/ALT(SGPT) 2.5 institutional ULN, Serum alkaline phosphatase 2.5 x ULN. Patients with bone metastases: alkaline phosphatase 5 x ULN
Albumin > 2.5 mg/dL
Glomerular filtration rate 60 mL/min as determined by the CKD-EPI equation (or reference methodology such as Iohexol or isotopic technic)
Urine dipstick for proteinuria < 2+. If urine dipstick is 2+, 24-hour urine must demonstrate < 1 g of protein in 24 hours
Normal blood pressure or adequately treated and controlled hypertension (systolic BP 140 mmHg and/or diastolic BP 90 mmHg)
Female patients of childbearing potential must have a negative serum pregnancy test within 8 days of initiating protocol therapy
Female patients of childbearing potential must agree to use contraceptive methods with a low failure rate (< 1% per year) during the treatment period and for 6 months after the last dose of study drugs
Male patients of childbearing potential must agree to use contraceptive methods with a low failure rate during the treatment period and for 6 months after the last dose of study drugs
Patient is capable of understanding and complying with the protocol and has signed the informed consent document
Patients affiliated to a social insurance regime

Exclusion Criteria

Residual toxicity from previous treatment grade 1, except for alopecia or peripheral neuropathy grade 2
Radiotherapy within 28 days before inclusion, except for palliative radiotherapy if patients recovered from all side effects
Congenital risk of bleeding, or acquired coagulopathy, or curative anti-coagulant therapies (except for low molecular weight heparin)
Active digestive bleeding within 3 months before inclusion
Patients pretreated with one of the experimental drugs, other immune checkpoint inhibitor anti-cancer drugs (anti-PD1, anti-PDL1, anti-CTLA4, ), or with ramucirumab
Uncontrolled high cholesterol or triglyceride grade 2
Uncontrolled intercurrent illness, including, but not limited to, ongoing or active infection, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, congestive heart failure-New York Heart Association Class III or IV, active ischemic heart disease, myocardial infarction within the previous six months, uncontrolled diabetes mellitus, gastric or duodenal ulceration diagnosed within the previous 6 months, chronic liver or renal disease, or severe malnutrition
Current peripheral neuropathy of Grade 3 according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v.5.0
Active, second potentially life-threatening cancer
Other malignancy within the last 5 years except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS). Patient with a history of localized malignancy diagnosed over 5 years ago may be eligible provided he completed her adjuvant systemic therapy and remains free of recurrent or metastatic disease
Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this
Patients with vitiligo or alopecia
Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
Any chronic skin condition that does not require systemic therapy
Patients without active disease in the last 5 years may be included but only after consultation with the study physician
Major surgery within 28 days before cycle 1, day 1
Active infection requiring iv antibiotics at day 1 of cycle 1
Medical condition that requires chronic systemic steroid therapy or on any other form of immunosuppressive medication. For example, patients with autoimmune disease that requires systemic steroids or immunosuppression agents should be excluded. Replacement therapy (eg., thyroxine, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs, resulting in dyspnea at rest
Patient is positive for the human immunodeficiency virus (HIV), HepBsAg, or HCV RNA
Live vaccine within 28 days of planned start of study therapy
History of abdominal fistula, gastrointestinal perforation and/or intra-abdominal abscess within the previous 6 months
History of Type I or Type II diabetes mellitus requiring insulin
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins or Chinese Hamster Ovary (CHO) cell proteins or loperamide drug or excipient
Known hypersensitivity to any of the components of atezolizumab, bevacizumab or ipatasertib
Participation in other interventional clinical research that may interfere with the experimental drugs efficacy
History of severe or life-threatening skin adverse reaction on prior treatment with other immune-stimulatory anticancer agents
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note